Trials / Completed
CompletedNCT00149968
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 196 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of renal transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enteric-Coated Mycophenolate Sodium (EC-MPS) | Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-09-08
- Last updated
- 2020-02-11
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00149968. Inclusion in this directory is not an endorsement.